Researchers at Penn State discover a virus that kills cancer

The best part about it?  80% of you already have this virus.  It causes no symptoms and does not harm healthy cells but aggressively attacks cancer cells.

“Scientists at the Penn State College of Medicine said this week they have discovered a virus that is capable of killing all grades of breast cancer “within seven days” of first introduction in a laboratory setting.”  Read original article here

______________________________________________________

The new office is under construction!  Things are getting really exciting around here.  Just wanted to remind everyone from now until our grand opening you can purchase the 10 wellness treatment packages for $300.00.   Once things get humming down at Burlington Creek, I’m not sure when or if this offer will ever be repeated.  It might be a good idea to stock up now.  They never expire and can be shared with whom ever you want.

Cancer can heal on its own, if your doctor will allow it.

The fact is clear that in primitive societies, people don’t die of cancer. This is supposed to be because they are healthier and eat properly. But who dares think the unthinkable: that the cause of the problem is doctors and when you don’t have them, cancer is insignificant?

It’s only when doctors using Western methods get involved that cancer actually becomes a problem at all. Then it’s suddenly a serious and probably fatal condition.

But it may be time for a re-think. Yesterday a major study was published which could change EVERYTHING doctors know and think about cancer.   (continue reading here)

You don’t have to be afraid of cancer any longer

Macrophage Activation May Suppress Breast Cancer Metastasis

By David Douglas

NEW YORK FEB 20, 2008 (Reuters Health) – Vitamin D-binding protein-derived macrophage activating factor (Gc-MAF) appears to be an effective immunotherapeutic agent in patients with metastatic breast cancer, according to US and Japanese researchers.

“Serum vitamin D-binding protein – known as Gc protein – is the precursor of the principal macrophage activating factor,” lead investigator Dr. Nobuto Yamamoto told Reuters Health.

“Treatment of purified Gc protein with beta-galactosidase and sialidase generates Gc-MAF,” he added, “the most potent macrophage activating factor ever discovered, which produces no side effect in humans.”

Dr. Yamamoto of the Socrates Institute for Therapeutic Immunology, Philadelphia and colleagues note that in vitro studies show that macrophages treated with Gc-MAF have a highly tumoricidal effect in mammary adenocarcinomas.

To investigate whether the approach can be effective in humans, the researchers studied 16 non-anemic breast cancer patients who were given “a minute amount – 100 nanograms per week – of Gc-MAF,” Dr. Yamamoto said.

The researchers found that after 16 to 22 Gc-MAF doses, initially elevated nagalase levels, which reflect the tumor burden, fell to those found in healthy controls. Follow-up over 4 years showed that the level remained low and that there was no tumor recurrence, they report in the January 15th issue of The International Journal of Cancer.

The findings, the team concludes, clearly demonstrate “the importance of focusing cancer immunotherapy on macrophage activation.”

International Journal Cancer. 2008 Jan 15; 122(2):461-7.

Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (Gc-MAF).

Yamamoto N, Suyama H, Yamamoto N, Ushijima N.

Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, PA 19126-3305, USA. nobutoyama@verizon.net

Serum vitamin D3-binding protein (Gc protein) is the precursor for the principal macrophage activating factor (MAF). The MAF precursor activity of serum Gc protein of breast cancer patients was lost or reduced because Gc protein was deglycosylated by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells. Patient serum Nagalase activity is proportional to tumor burden. The deglycosylated Gc protein cannot be converted to MAF, resulting in no macrophage activation and immunosuppression. Stepwise incubation of purified Gc protein with immobilized beta-galactosidase and sialidase generated probably the most potent macrophage activating factor (termed Gc-MAF) ever discovered, which produces no adverse effect in humans. Macrophages treated in vitro with Gc-MAF (100 pg/ml) are highly tumoricidal to mammary adenocarcinomas. Efficacy of Gc-MAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of Gc-MAF (100 ng). As Gc-MAF therapy progresses, the MAF precursor activity of patient Gc protein increased with a concomitant decrease in serum Nagalase. Because of proportionality of serum Nagalase activity to tumor burden, the time course progress of Gc-MAF therapy was assessed by serum Nagalase activity as a prognostic index. These patients had the initial Nagalase activities ranging from 2.32 to 6.28 nmole/min/mg protein. After about 16-22 administrations (approximately 3.5-5 months) of Gc-MAF, these patients had insignificantly low serum enzyme levels equivalent to healthy control enzyme levels, ranging from 0.38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years. Copyright 2007 Wiley-Liss, Inc.

Cancer Immunology, Immunotherapy 2008 July 57 (7): online

Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, Gc-MAF

Nobuto Yamamoto, Hirofumi Suyama, Hiroaki Nakazato, Nobuyuki Yamamoto and Yoshihiko Koga

Abstract: Serum vitamin D binding protein (Gc protein) is the precursor for the principal macrophage-activating factor (MAF). The MAF precursor activity of serum Gc protein of colorectal cancer patients was lost or reduced because Gc protein is deglycosylated by serum α-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells. Deglycosylated Gc protein cannot be converted to MAF, leading to immunosuppression. Stepwise treatment of purified Gc protein with immobilized β-galactosidase and sialidase generated the most potent macrophage-activating factor (Gc-MAF) ever discovered, but it produces no side effect in humans. Macrophages treated with Gc-MAF (100 pg/ml) develop an enormous variation of receptors and are highly tumoricidal to a variety of cancers indiscriminately. Administration of 100 nanogram (ng)/human maximally activates systemic macrophages that can kill cancerous cells. Since the half-life of the activated macrophages is approximately 6 days, 100 ng Gc-MAF was administered weekly to eight nonanemic colorectal cancer patients who had previously received tumor-resection but still carried significant amounts of metastatic tumor cells. As Gc-MAF therapy progressed, the MAF precursor activities of all patients increased and conversely their serum Nagalase activities decreased. Since serum Nagalase is proportional to tumor burden, serum Nagalase activity was used as a prognostic index for time course analysis of Gc-MAF therapy. After 32–50 weekly administrations of 100 ng Gc-MAF, all colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells. During 7 years after the completion of Gc-MAF therapy, their serum Nagalase activity did not increase, indicating no recurrence of cancer, which was also supported by the annual CT scans of these patients.

May 22, 2008

Put a lid on it Yoplait

Dear Citizen Activist,

October is Breast Cancer Awareness Month, and you may have already seen the ads touting Yoplait’s campaign against breast cancer, called Save Lids to Save Lives .

The company plans to donate 10 cents to the fight against breast cancer for every cup of yogurt with with a pink foil lid that consumers purchase.

Yoplait touts its yogurt as being healthy for women, but what’s inside is anything but.

The reality is that Yoplait yogurt is made with milk from cows that have been injected with a synthetic hormone called recombinant bovine growth hormone (called rBGH or rBST). Research indicates that there are numerous health concerns linked to the consumption of dairy from cows injected with rBGH – and breast cancer is one of them.

The bottom line is that rBGH is unsafe – and unnecessary. In fact, the use of rBGH has already been banned in Australia, Canada, Japan, and all 27 countries in the European Union. In addition to the many companies that offer rBGH-free products, big-box stores and food and beverage chains like Wal-Mart, Publix, Kroger, Starbucks, and Chipotle have committed to reducing or completely eliminating dairy products made with rBGH from their stores. If these companies can do it, Yoplait can too.

In support of Breast Cancer Awareness Month, and in solidarity with millions of women, ask Yoplait to do the right thing and put a lid on rBGH.

Mammograms cause cancer

Everyone knows radiation causes cancer. 

Most everyone knows that the breast tissue is some of the most sensitive tissue to radiation damage in the body.

Ionizing radiation causes double and multiple strand breaks in DNA and is accepted as a primary cause of cancer. Since the 1970s, the gold standard for breast cancer detection, in the Western world, has been screening mammography.

2004 Radiation Research
The Neoplastic Transformation Potential of Mammography X-Rays
To help resolve the controversy regarding the risk of mammography breast screening, a study was carried out with a grant to the University of Birmingham, UK.  A comparison was made using an actual low-dose mammogram X-ray machine and a standard high-dose X-ray (chest X-ray). Results suggested that the risks (of developing cancer) associated with mammogram screening may be approximately five times higher than previously assumed (which was 1%), making the estimated increased risk of 5% for each exposure. The authors suggested that the risk-benefit relationship of mammography exposure clearly needs to be re-evaluated.

celldoubling.jpg

Enter thermal imaging:

The above image is an infrared image of a developing breast tumor appoximately 2-3 years before a mammogram could pick it up.

Thermal imaging is a technology that has been available for 30 years but is actively suppressed by General Electric because it competes with the very profitable mammogram machines.  It is completely passive, no squashing, no radiation, no potential harm what so ever!

I have waited for 12 years for someone else to figure this out and have finally concluded that this is not going to happen in the medical community without a little push.  So, I am negotiating the purchase of a thermal imaging machine to be placed in my clinic.  Very shortly I will be able to begin screenings for many disease processes that show up as cellular inflammation years before a physical tumor will be detectable.  For example, diabetic avascular necrosis, skin cancer, varicose viens, heart disease, arthritis, etc.  All without radiation exposure!!

A breast thermogram will be a 5 view panel for $175.00, (about half what a mammogram costs)  Area exams for nerve damage or strains will be $50.00 per image needed to properly view the problem.  Please contact me to schedule your exams.  (The camera costs well over $30K)

At this time this is not covered by insurance, but with your help I beleive we can get that changed shortly.  The early detection capabilities of this technology will reduce the costs of health care tremendously within a very short time.

DrD